Inozyme Pharma is a biotechnology company developing novel medicines to treat rare disorders of calcification. These diseases are characterized by PPi imbalances, which lead to over-calcification of soft tissues and under-mineralization of bone. Founded in 2016, the company possesses a deep understanding of the biology of calcification which it uses to develop new medicines with the potential to drastically improve the standard-of-care and change treatment paradigms. Inozyme’s lead candidate is an enzyme replacement therapy designed to treat ENPP1 Deficiency (GACI type 1 and ARHR2) and ABCC6 Deficiency (GACI type 2 and PXE) for which insufficient treatment options currently exist.